Logo image of FOXO

FOXO TECHNOLOGIES INC (FOXO) Stock Fundamental Analysis

NYSEARCA:FOXO - NYSE Arca - US3514713052 - Common Stock - Currency: USD

0.0841  -0.02 (-22.84%)

Fundamental Rating

1

FOXO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 285 industry peers in the Software industry. Both the profitability and financial health of FOXO have multiple concerns. FOXO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

FOXO had negative earnings in the past year.
FOXO had a negative operating cash flow in the past year.
FOXO Yearly Net Income VS EBIT VS OCF VS FCFFOXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

FOXO's Return On Assets of -26.81% is on the low side compared to the rest of the industry. FOXO is outperformed by 71.58% of its industry peers.
Industry RankSector Rank
ROA -26.81%
ROE N/A
ROIC N/A
ROA(3y)-1503.46%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FOXO Yearly ROA, ROE, ROICFOXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

With a Gross Margin value of 0.97%, FOXO is not doing good in the industry: 87.72% of the companies in the same industry are doing better.
The Profit Margin and Operating Margin are not available for FOXO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FOXO Yearly Profit, Operating, Gross MarginsFOXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -10K -20K -30K

0

2. Health

2.1 Basic Checks

FOXO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FOXO has more shares outstanding
The debt/assets ratio for FOXO is higher compared to a year ago.
FOXO Yearly Shares OutstandingFOXO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2M 4M 6M
FOXO Yearly Total Debt VS Total AssetsFOXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -7.43, we must say that FOXO is in the distress zone and has some risk of bankruptcy.
FOXO has a worse Altman-Z score (-7.43) than 85.26% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.43
ROIC/WACCN/A
WACC8.15%
FOXO Yearly LT Debt VS Equity VS FCFFOXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 -10M -20M

2.3 Liquidity

A Current Ratio of 0.08 indicates that FOXO may have some problems paying its short term obligations.
The Current ratio of FOXO (0.08) is worse than 95.44% of its industry peers.
A Quick Ratio of 0.08 indicates that FOXO may have some problems paying its short term obligations.
FOXO's Quick ratio of 0.08 is on the low side compared to the rest of the industry. FOXO is outperformed by 95.44% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
FOXO Yearly Current Assets VS Current LiabilitesFOXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 10M 20M 30M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.84% over the past year.
FOXO shows a strong growth in Revenue. In the last year, the Revenue has grown by 198.00%.
The Revenue has been growing by 34.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)94.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.39%
Revenue 1Y (TTM)198%
Revenue growth 3Y34.2%
Revenue growth 5YN/A
Sales Q2Q%11860%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FOXO Yearly Revenue VS EstimatesFOXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 100K 200K 300K 400K 500K

0

4. Valuation

4.1 Price/Earnings Ratio

FOXO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FOXO Price Earnings VS Forward Price EarningsFOXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FOXO Per share dataFOXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for FOXO!.
Industry RankSector Rank
Dividend Yield N/A

FOXO TECHNOLOGIES INC

NYSEARCA:FOXO (4/17/2025, 8:21:45 PM)

0.0841

-0.02 (-22.84%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-11 2024-11-11
Earnings (Next)06-04 2025-06-04
Inst Owners2.69%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap3.01M
AnalystsN/A
Price TargetN/A
Short Float %8.88%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.04
BVpS-0.49
TBVpS-1.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 0.97%
FCFM N/A
ROA(3y)-1503.46%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z -7.43
F-Score2
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.39%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)198%
Revenue growth 3Y34.2%
Revenue growth 5YN/A
Sales Q2Q%11860%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y80.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.22%
OCF growth 3YN/A
OCF growth 5YN/A